Lipoprotein and Apolipoproteins With Metabolic Liver Diseases

Theranostic Translation Applications Against Viral, Metabolic Liver Diseases and Hepatic Oncogenesis: Lipoprotein and Apolipoproteins at a Crossroad

Theranostic translation applications against viral, metabolic liver diseases and hepatic oncogenesis: lipoprotein and apolipoproteins at a crossroad

An intimate link between microbial infections, metabolic changes and oncogenesis has been drawn attentions increasingly, indicating a crossroad leading to pathogenesis and disease progression. Globally the burden of hepatitis B and C virus infections is 450 and 185 millions, respectively and chronic hepatitis disease causes a high risk of liver cirrhosis, hepatocellular carcinoma and metabolic disorders

Inclusion Criteria:

1. above 20 years
2. nonalcoholic fatty liver disease
3. Non-Alcoholic Steatohepatitis

Exclusion Criteria:

1. alcohonic hepatitis 2. Autoimmune liver disease 3. HIV postive

-